Dimerix's DMX-200 Shows Promise in Phase 3 Trial for Rare Kidney Disease FSGS

• Dimerix Limited's DMX-200 demonstrates successful interim results in a Phase 3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease.
• The trial included 72 patients and showed potential in treating FSGS, which currently has no approved drugs globally, marking a significant advancement.
• Dimerix plans to expand the trial to include more countries, such as China, and broaden the patient base to include children over 12 years old.
• The treatment, co-invented by researchers at the Harry Perkins Institute, could prevent kidney damage and the need for dialysis or transplantation in FSGS patients.

Dimerix Limited has announced positive interim results from its Phase 3 clinical trial of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS), a rare and progressive kidney disease. The trial's success marks a significant step forward in addressing a condition with no currently approved treatments. FSGS affects both children and adults, leading to inflammation and scarring of the kidney's filtering units, often resulting in kidney failure requiring dialysis or transplantation within five years. Notably, approximately 40% of kidney transplant recipients experience recurrent FSGS in the transplanted organ.

DMX-200: A Potential Breakthrough

DMX-200, the investigational treatment, targets inflammatory and respiratory diseases. The Phase 3 trial involved 72 patients and demonstrated promising results, paving the way for expanded clinical sites in more countries, including China, and the inclusion of children over the age of 12 in future studies. The drug was co-invented by Professor Kevin Pfleger from the Harry Perkins Institute of Medical Research, along with Dr. James Williams and Liddy McCall.

Scientific Collaboration and Future Directions

Professor Pfleger stated, "It was working as a cohesive team that lifted the science to achieve this translationally-focused outcome. We congratulate the Dimerix team for delivering our early vision to treat FSGS patients and potentially future kidney diseases. We look forward to seeing their continued progress". Ms. McCall added, "It is great to have contributed to meaningful translation benefiting patients with FSGS, and to see future new applications derived using our original systemic analysis of heteromer drug target interactions". Dr. Williams noted the successful translation of medical research outcomes, particularly in a disease with such a high unmet need.

The Harry Perkins Institute and Dimerix continue their collaboration through the Health Translation Group, supporting the translation of emerging intellectual property from Western Australian medical research organizations.